A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy

Clinical trial NCT07378969 · RECRUITING

Trial details

NCT number: NCT07378969
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Study type: OBSERVATIONAL

Secondary Malignancies of T-cell Origin

Start date: 2026-03-23
Primary completion: 2039-08-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.